2017台灣生技月閉幕, 逾350場媒合會, 生技月讓世界看見台灣
亞洲生技產業年度盛會–2017台灣生技月(BioTaiwan 2017)活動於6月28日-7月2日於南港舉辦，並於今日(7/2)閉幕。總計今年共有超過600家國內外指標性大廠與1310個攤位參與生技展，吸引超過9萬人次進場參觀，促成近350場的商機媒合。
Read more生物技術
OBI Pharma signs agreement with Abzena for ADC linker technology
Cambridge, UK-headquartered drug development technology and services provider Abzena plc, has signed a licensing agreement and a master services and clinical supply agreement with Taipei, Taiwan biotech OBI Pharma (TPEx: 4174) for its novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI’s proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer.
Read more
BioBusiness Asia 2017 examines global trends, new technologies shaping healthcare
BioBusiness Asia, the two-day business-themed life sciences conference held annually in Taipei, Taiwan, recently concluded. A part of the week-long BioTaiwan festival of life science-focused events, the conference this year had a wide range of session themes with a particular emphasis on emerging technologies such as precision medicine, next generation sequencing, artificial intelligence (AI), synthetic biology, cancer immunotherapy, and digital health.
Read more
Taiwan joins forces with Insilico Medicine to apply AI to biomedical research
The Development Center for Biotechnology (DCB), the Medical and Pharmaceutical Industrial Technology Development Center (PITDC), and Taipei Medical University (TMU), three of Taiwan’s premier biomedical institutions, have teamed up with Baltimore-based Insilico Medicine to develop groundbreaking research in applied A.I. for biomedical science.
Read more
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera
AOP Orphan Pharmaceuticals AG of Vienna, Austria (AOP Orphan) and Taipei, Taiwan-headquartered PharmaEssentia Corporation (TPEx: 6446) together announced the latest results from three clinical studies on Ropeginterferon alfa-2b for patients with Polycythemia Vera (PV) presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain.
Read more
Lumosa Therapeutics’ LT3001 for stroke receives FDA approval to begin clinical trials
Taipei, Taiwan-headquartered Lumosa Therapeutics Co., Ltd. has announced that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials.
Read more